Enovis vs Edwards Lifesciences
ENOV and EW side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENOV and EW compare
Edwards Lifesciences is the larger company, worth 46 times as much as Enovis ($53.0B against $1.1B).
Edwards Lifesciences grew revenue faster over the last twelve months (14.6% versus 4.9% for Enovis).
Edwards Lifesciences keeps more of each dollar of sales as profit, with a net margin of 15.4% compared with −48.0% at Enovis.
Edwards Lifesciences scores higher on the StockData Score (10 against 8 for Enovis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENOV | EW |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $53.0B |
| Share price | $19.91 | $92.01 |
| Change, 1 year | −37.8% | 11.3% |
| Change, 5 years | −87.5% | −22.5% |
| Beta (5Y) | 1.22 | 1.00 |
| Employees | 7,802 | 16K |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 4 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 0 | 3 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 52.9× |
| P/S | 0.5× (better) | 8.1× |
| P/B | 0.8× (better) | 5.0× |
| EV/EBITDA | 7.8× (better) | 30.7× |
| P/FCF | 18.0× (better) | 37.0× |
| FCF yield | 5.5% (better) | 2.7% |
| Fair value | $81.47 | $65.85 |
| Margin of safety | 75.6% (better) | −39.7% |
| Growth | ||
| Revenue growth (TTM) | 4.9% | 14.6% (better) |
| Revenue growth, 5Y average | 14.9% (better) | 6.7% |
| Net income growth (TTM) | – | −75.8% |
| EPS growth (TTM) | – | −75.0% |
| EPS growth, 5Y average | – | 7.1% |
| Profitability | ||
| Gross margin | 61.1% | 77.8% (better) |
| Operating margin | −45.1% | 22.3% (better) |
| Net margin | −48.0% | 15.4% (better) |
| FCF margin | 2.8% | 22.0% (better) |
| Return on equity | −54.3% | 9.5% (better) |
| Return on invested capital | −24.5% | 14.3% (better) |
| Financial health | ||
| Debt / equity | 0.87 | 0.06 (better) |
| Net debt / EBITDA | 4.12 (better) | −2.26 |
| Interest coverage | −30.9× | – |
| Current ratio | 1.98 | 4.52 (better) |
| Altman Z-score | −0.35 | 12.90 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 2.3% |
| Shareholder yield | 0.00% | 2.3% (better) |
| Ownership | ||
| Held by institutions | 122% | 91.0% |
| Held by insiders | 2.7% | 0.22% |
| Insider net buying, 12 months | $717K (better) | −$27.7M |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 18.8% | 1.7% |
Go deeper
- ENOV stock overview
- ENOV income statement
- ENOV valuation and score
- EW stock overview
- EW income statement
- EW valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.